Guggenheim raised the firm’s price target on Roivant Sciences (ROIV) to $21 from $15 and keeps a Buy rating on the shares after the company announced positive results from the Phase 3 VALOR Study of brepocitinib in treating dermatomyositis. ) Brepo 30 mg achieved a “remarkable” mean total improvement score of 46.5, notes the analyst, who updated the firm’s model to include 100% odds of success of brepo in DM and estimates peak sales of about $2B based on about 50% peak penetration.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ROIV:
- Roivant Sciences price target raised to $20 from $16 at JPMorgan
- Roivant Sciences price target raised to $20 from $18 at H.C. Wainwright
- Yaron Werber’s Buy Rating Highlights Brepocitinib’s Potential as a Leading Treatment for Dermatomyositis
- Roivant Sciences rises 11.2%
- General Mills reports Q1 beat, Rithm to acquire Paramount Group: Morning Buzz